FDA's Dermatologic Drugs Advisory Committee
This article was originally published in The Tan Sheet
Executive Summary
Discussion topics for the panel's Sept. 22-23 meeting include the fungal nail infection onychomycosis and the "determination of endpoints for clinical trials investigating treatment of onychomycosis," an Aug. 16 Federal Register notice states. The meeting will be held in Conference Rooms D&E of FDA's Parklawn Building beginning at 8:30 a.m. on both days